drugset / Trial / NCT05965154
Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, one-arm exploratory second-line study of carrilizumab combined with bevacizumab plus capecitabine in relapsed metastatic squamous cell carcinoma of the head and neck.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2025-04-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | Carrilizumab | Monoclonal antibody | 200 mg | Intravenous |